Skip to content
AI IntelligenceApr 24, 2026Secondary Market
Article

IBRX

ImmunityBio, Inc. (IBRX) is the subject of a securities fraud class action lawsuit. The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the lawsuit against the Company. The details were filed in an SEC 8-K.

Data Cube AI EditorialSource: PR Newswire
01

Source Brief

ImmunityBio, Inc. (IBRX) is the subject of a securities fraud class action lawsuit. The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the lawsuit against the Company. The details were filed in an SEC 8-K.